Akebia Therapeutics (AKBA) Retained Earnings (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Retained Earnings data on file, last reported at $6000.0 in Q1 2026.

• On a quarterly basis, Retained Earnings rose 100.0% year-over-year to $6000.0 in Q1 2026; TTM through Mar 2026 was $6000.0, a 100.0% increase from a year earlier, with the FY2025 full-year figure at $6000.0, changed 0.0% from the prior year.
• Retained Earnings for Q1 2026 stood at $6000.0, roughly flat from $6000.0 in the prior quarter.
• Over the last five years, Retained Earnings for AKBA reached as high as $6000.0 in Q4 2022 and fell as low as -$1.7 billion in Q1 2025.
• Historically, Retained Earnings has averaged -$1.0 billion across 5 years, with a median of -$1.6 billion in 2022.
• Across the five-year window, Retained Earnings soared 100.0% in 2022 and slumped 27870900.0% in 2025, its largest moves.
• Year by year, Retained Earnings stood at $6000.0 in 2022, then tumbled by 26815933.33% to -$1.6 billion in 2023, then surged by 100.0% to $6000.0 in 2024, then changed by 0.0% to $6000.0 in 2025, then changed by 0.0% to $6000.0 in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were $6000.0 in Q1 2026, $6000.0 in Q4 2025, and -$1.7 billion in Q3 2025.